Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk

Jonine D. Figueroa, Núria Malats, Nathaniel Rothman, Francisco X. Real, Debra Silverman, Manolis Kogevinas, Stephen Chanock, Meredith Yeager, Robert Welch, Mustafa Dosemeci, Adonina Tardón, Consol Serra, Alfredo Carrato, Reina García-Closas, Gemma Castaño-Vinyals, Montserrat García-Closas

Research output: Contribution to journalArticle

Abstract

The double-strand break DNA repair (DSBR) pathway is implicated in maintaining genomic stability and therefore could affect bladder cancer risk. Here we present data evaluating 39 single-nucleotide polymorphisms (SNPs) in seven candidate genes whose products are involved in DNA break sensing (NBS1, BRCA1 interacting genes BRIP1 and ZNF350), non-homologous end-joining (NHEJ) DNA repair (X RCC4) and homologous recombination (HR) repair (R AD51, XRCC2 and XRCC3). SNPs for RAD51 and XRCC2 covered most of the common variation. Associations with bladder cancer risk were evaluated in 1150 newly diagnosed cases of urinary bladder transitional cell carcinomas and 1149 controls conducted in Spain during 1997-2001. We found that the genetic variants evaluated significantly contributed to bladder cancer risk (global likelihood ratio test P = 0.01). Subjects with the ZNF350 R501S (rs2278415) variant allele showed significantly reduced risk compared with common homozygote variants, odds ratio (OR) [95% confidence interval (95% CI)]: 0.76 (0.62-0.93) per variant allele. Carriers of a putative functional SNP in intron 7 of XRCC4 (rs1805377) had significantly increased bladder cancer risk compared with common homozygotes: 1.33 (1.08-1.64) per variant allele. Lastly, XRCC2 homozygote variants for three promoter SNPs (rs10234749, rs6464268, rs3218373) and one non-synonymous SNP (rs3218536, R188H) were associated with reduced bladder cancer risk (ORs ranging from 0.36 to 0.50 compared with common homozygotes). Meta-analysis for XRCC3 T241M (rs861539) had a significant small increase in risk among homozygote variants: OR (95% CI) = 1.17 (1.00-1.36). Results from this study provide evidence for associations between variants in genes in the DSBR pathway and bladder cancers risk that warrant replication in other study populations.

Original languageEnglish (US)
Pages (from-to)1788-1793
Number of pages6
JournalCarcinogenesis
Volume28
Issue number8
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Homozygote
Single Nucleotide Polymorphism
DNA Repair
Alleles
Odds Ratio
Confidence Intervals
BRCA1 Gene
Recombinational DNA Repair
DNA Breaks
Transitional Cell Carcinoma
Genomic Instability
Spain
Introns
Genes
Meta-Analysis
Urinary Bladder
Population

ASJC Scopus subject areas

  • Cancer Research

Cite this

Figueroa, J. D., Malats, N., Rothman, N., Real, F. X., Silverman, D., Kogevinas, M., ... García-Closas, M. (2007). Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis, 28(8), 1788-1793. https://doi.org/10.1093/carcin/bgm132

Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. / Figueroa, Jonine D.; Malats, Núria; Rothman, Nathaniel; Real, Francisco X.; Silverman, Debra; Kogevinas, Manolis; Chanock, Stephen; Yeager, Meredith; Welch, Robert; Dosemeci, Mustafa; Tardón, Adonina; Serra, Consol; Carrato, Alfredo; García-Closas, Reina; Castaño-Vinyals, Gemma; García-Closas, Montserrat.

In: Carcinogenesis, Vol. 28, No. 8, 08.2007, p. 1788-1793.

Research output: Contribution to journalArticle

Figueroa, JD, Malats, N, Rothman, N, Real, FX, Silverman, D, Kogevinas, M, Chanock, S, Yeager, M, Welch, R, Dosemeci, M, Tardón, A, Serra, C, Carrato, A, García-Closas, R, Castaño-Vinyals, G & García-Closas, M 2007, 'Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk', Carcinogenesis, vol. 28, no. 8, pp. 1788-1793. https://doi.org/10.1093/carcin/bgm132
Figueroa JD, Malats N, Rothman N, Real FX, Silverman D, Kogevinas M et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007 Aug;28(8):1788-1793. https://doi.org/10.1093/carcin/bgm132
Figueroa, Jonine D. ; Malats, Núria ; Rothman, Nathaniel ; Real, Francisco X. ; Silverman, Debra ; Kogevinas, Manolis ; Chanock, Stephen ; Yeager, Meredith ; Welch, Robert ; Dosemeci, Mustafa ; Tardón, Adonina ; Serra, Consol ; Carrato, Alfredo ; García-Closas, Reina ; Castaño-Vinyals, Gemma ; García-Closas, Montserrat. / Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. In: Carcinogenesis. 2007 ; Vol. 28, No. 8. pp. 1788-1793.
@article{4c73d14bacbf472a875ca62446ba6756,
title = "Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk",
abstract = "The double-strand break DNA repair (DSBR) pathway is implicated in maintaining genomic stability and therefore could affect bladder cancer risk. Here we present data evaluating 39 single-nucleotide polymorphisms (SNPs) in seven candidate genes whose products are involved in DNA break sensing (NBS1, BRCA1 interacting genes BRIP1 and ZNF350), non-homologous end-joining (NHEJ) DNA repair (X RCC4) and homologous recombination (HR) repair (R AD51, XRCC2 and XRCC3). SNPs for RAD51 and XRCC2 covered most of the common variation. Associations with bladder cancer risk were evaluated in 1150 newly diagnosed cases of urinary bladder transitional cell carcinomas and 1149 controls conducted in Spain during 1997-2001. We found that the genetic variants evaluated significantly contributed to bladder cancer risk (global likelihood ratio test P = 0.01). Subjects with the ZNF350 R501S (rs2278415) variant allele showed significantly reduced risk compared with common homozygote variants, odds ratio (OR) [95{\%} confidence interval (95{\%} CI)]: 0.76 (0.62-0.93) per variant allele. Carriers of a putative functional SNP in intron 7 of XRCC4 (rs1805377) had significantly increased bladder cancer risk compared with common homozygotes: 1.33 (1.08-1.64) per variant allele. Lastly, XRCC2 homozygote variants for three promoter SNPs (rs10234749, rs6464268, rs3218373) and one non-synonymous SNP (rs3218536, R188H) were associated with reduced bladder cancer risk (ORs ranging from 0.36 to 0.50 compared with common homozygotes). Meta-analysis for XRCC3 T241M (rs861539) had a significant small increase in risk among homozygote variants: OR (95{\%} CI) = 1.17 (1.00-1.36). Results from this study provide evidence for associations between variants in genes in the DSBR pathway and bladder cancers risk that warrant replication in other study populations.",
author = "Figueroa, {Jonine D.} and N{\'u}ria Malats and Nathaniel Rothman and Real, {Francisco X.} and Debra Silverman and Manolis Kogevinas and Stephen Chanock and Meredith Yeager and Robert Welch and Mustafa Dosemeci and Adonina Tard{\'o}n and Consol Serra and Alfredo Carrato and Reina Garc{\'i}a-Closas and Gemma Casta{\~n}o-Vinyals and Montserrat Garc{\'i}a-Closas",
year = "2007",
month = "8",
doi = "10.1093/carcin/bgm132",
language = "English (US)",
volume = "28",
pages = "1788--1793",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk

AU - Figueroa, Jonine D.

AU - Malats, Núria

AU - Rothman, Nathaniel

AU - Real, Francisco X.

AU - Silverman, Debra

AU - Kogevinas, Manolis

AU - Chanock, Stephen

AU - Yeager, Meredith

AU - Welch, Robert

AU - Dosemeci, Mustafa

AU - Tardón, Adonina

AU - Serra, Consol

AU - Carrato, Alfredo

AU - García-Closas, Reina

AU - Castaño-Vinyals, Gemma

AU - García-Closas, Montserrat

PY - 2007/8

Y1 - 2007/8

N2 - The double-strand break DNA repair (DSBR) pathway is implicated in maintaining genomic stability and therefore could affect bladder cancer risk. Here we present data evaluating 39 single-nucleotide polymorphisms (SNPs) in seven candidate genes whose products are involved in DNA break sensing (NBS1, BRCA1 interacting genes BRIP1 and ZNF350), non-homologous end-joining (NHEJ) DNA repair (X RCC4) and homologous recombination (HR) repair (R AD51, XRCC2 and XRCC3). SNPs for RAD51 and XRCC2 covered most of the common variation. Associations with bladder cancer risk were evaluated in 1150 newly diagnosed cases of urinary bladder transitional cell carcinomas and 1149 controls conducted in Spain during 1997-2001. We found that the genetic variants evaluated significantly contributed to bladder cancer risk (global likelihood ratio test P = 0.01). Subjects with the ZNF350 R501S (rs2278415) variant allele showed significantly reduced risk compared with common homozygote variants, odds ratio (OR) [95% confidence interval (95% CI)]: 0.76 (0.62-0.93) per variant allele. Carriers of a putative functional SNP in intron 7 of XRCC4 (rs1805377) had significantly increased bladder cancer risk compared with common homozygotes: 1.33 (1.08-1.64) per variant allele. Lastly, XRCC2 homozygote variants for three promoter SNPs (rs10234749, rs6464268, rs3218373) and one non-synonymous SNP (rs3218536, R188H) were associated with reduced bladder cancer risk (ORs ranging from 0.36 to 0.50 compared with common homozygotes). Meta-analysis for XRCC3 T241M (rs861539) had a significant small increase in risk among homozygote variants: OR (95% CI) = 1.17 (1.00-1.36). Results from this study provide evidence for associations between variants in genes in the DSBR pathway and bladder cancers risk that warrant replication in other study populations.

AB - The double-strand break DNA repair (DSBR) pathway is implicated in maintaining genomic stability and therefore could affect bladder cancer risk. Here we present data evaluating 39 single-nucleotide polymorphisms (SNPs) in seven candidate genes whose products are involved in DNA break sensing (NBS1, BRCA1 interacting genes BRIP1 and ZNF350), non-homologous end-joining (NHEJ) DNA repair (X RCC4) and homologous recombination (HR) repair (R AD51, XRCC2 and XRCC3). SNPs for RAD51 and XRCC2 covered most of the common variation. Associations with bladder cancer risk were evaluated in 1150 newly diagnosed cases of urinary bladder transitional cell carcinomas and 1149 controls conducted in Spain during 1997-2001. We found that the genetic variants evaluated significantly contributed to bladder cancer risk (global likelihood ratio test P = 0.01). Subjects with the ZNF350 R501S (rs2278415) variant allele showed significantly reduced risk compared with common homozygote variants, odds ratio (OR) [95% confidence interval (95% CI)]: 0.76 (0.62-0.93) per variant allele. Carriers of a putative functional SNP in intron 7 of XRCC4 (rs1805377) had significantly increased bladder cancer risk compared with common homozygotes: 1.33 (1.08-1.64) per variant allele. Lastly, XRCC2 homozygote variants for three promoter SNPs (rs10234749, rs6464268, rs3218373) and one non-synonymous SNP (rs3218536, R188H) were associated with reduced bladder cancer risk (ORs ranging from 0.36 to 0.50 compared with common homozygotes). Meta-analysis for XRCC3 T241M (rs861539) had a significant small increase in risk among homozygote variants: OR (95% CI) = 1.17 (1.00-1.36). Results from this study provide evidence for associations between variants in genes in the DSBR pathway and bladder cancers risk that warrant replication in other study populations.

UR - http://www.scopus.com/inward/record.url?scp=34548056355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548056355&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgm132

DO - 10.1093/carcin/bgm132

M3 - Article

VL - 28

SP - 1788

EP - 1793

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 8

ER -